 Dendreon Corp filed for Chapter  bankruptcy protection on Monday after coming to terms with senior lenders that backed the biopharmaceutical company when hopes of big profits from its pricey cancer drug were running high Those lenders are now poised to take over the company or sell it Unless a buyer can be found that is willing to continue producing Provenge a novel treatment for prostate cancer that never really gained traction in the market Dendreon and its longpromising drug will belong to lenders